Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11387325 | 0.89 | CES2 (0.46) | CES2CES1ALDH1A1POLBHPGD | |
| SCHEMBL20659147 | 0.87 | ALDH1A1 (0.47) | CES2CES1ALDH1A1POLBHPGD | |
| SCHEMBL20659154 | 0.85 | ALDH1A1 (0.52) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL20659379 | 0.85 | CES2 (0.48) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL1431970 | 0.83 | CES2 (0.56) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL10768438 | 0.81 | CES2 (0.54) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL27401657 | 0.81 | ALDH1A1 (0.58) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL11743794 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL9988312 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1POLBTSHR | |
| SCHEMBL2585991 | 0.79 | CES2 (0.52) | CES2CES1ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238676-B2 | Purine derivatives | PFIZER INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1296996-A1 | PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| WO-2002000676-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| EP-0717742-A1 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007279-A2 | PROCESS FOR THE PREPARATION OF INDOLIZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CES2 1946/4885CES1 1272/4885ALDH1A1 226/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CES2 1946/4885CES1 1272/4885ALDH1A1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.